查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006255

癌症基因治疗市场：依载体类型、治疗方法、适应症、疾病阶段和最终用户划分－2026-2032年全球市场预测

Cancer Gene Therapy Market by Vector Type, Therapy Type, Indication, Stage, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，癌症基因治疗市场价值将达到 33 亿美元，到 2026 年将成长至 39.7 亿美元，到 2032 年将达到 118.1 亿美元，复合年增长率为 19.96%。

主要市场统计数据
基准年 2025 33亿美元
预计年份：2026年 39.7亿美元
预测年份 2032 118.1亿美元
复合年增长率 (%) 19.96%

我们将透过整合科学进步、递送技术创新和切实可行的转化策略，加速临床上可行的癌症基因疗法的出现。

癌症基因疗法正处于一个转折点，数十年的基础科学成果正与实际临床应用和工业化生产相融合。载体工程、递送方法和分子标靶的最新进展已将许多概念从实验室原理验证试验推进到人体试验，并在某些情况下最终应用于临床。同时，基因组分析、患者分层和伴随诊断技术的进步使得治疗药物能够更精准地匹配生物学特征明确的患者群体，从而提高临床疗效，并为优先研发提供宝贵资讯。

新的技术突破、监管变革和不断发展的经营模式正在重塑治疗方法的设计、生产和患者获取方式。

近年来，癌症基因治疗领域发生了变革性的变化，这主要源于技术、监管和商业动态的融合，从根本上改变了专案风险评估和上市时间预测。在技​​术层面，载体设计的改进，包括优化趋向性和降低免疫抗原性，以及脂质体等非病毒递送平台的创新，正在拓展其适用范围和患者群体。同时，生产技术的进步使得更可靠的规模化生产成为可能，从而生产出产量更高、分析控制更稳定的高品质载体。这降低了批次间的差异，并支持多中心临床开发。

评估美国关税政策变化对原料采购、供应链韧性和跨境临床营运的营运和策略影响。

影响跨境贸易的政策介入措施，例如关税调整及相关海关措施，正开始对生技药品和先进治疗材料的采购、供应商选择和供应链发展产生影响。关税结构的变化可能会增加进口原料的成本，包括特殊脂质、质体DNA生产试剂、病毒载体原料和一次性生产组件。这些增加的投入成本可能导致早期研发公司和契约製造组织（CMO）的营运预算增加，进而可能影响供应商整合、近岸采购或垂直整合等决策。

对临床和商业性细分进行详细分析，揭示了载体选择、治疗方法、适应症复杂性、开发阶段和最终用户如何塑造策略重点。

一个精细的细分框架阐明了载体类型、治疗方法、适应症、研发阶段和最终用户等因素如何交汇于临床潜力和商业性可行性。按载体类型分析表明，非病毒载体和病毒载体之间的差异决定了研发重点。非病毒载体包括脂质奈米颗粒、物理方法和聚合物奈米颗粒，其优点在于生产规模化和降低长期免疫抗原性风险。另一方面，病毒载体包括腺结合病毒、腺病毒、慢病毒和逆转录病毒平台，其优势在于能够实现持续的转基因表达和细胞特异性递送，但需要专门的生产过程和安全性监测。此外，治疗方法类型区分了体外（ex vivo）和体内（in vivo）方法。体外方法利用自体或异体细胞操作流程，而体内策略则强调直接全身或局部给予组织。

美洲、欧洲、中东和非洲以及亚太地区的区域竞争格局和病患准入趋势正在塑造差异化的开发和商业化策略。

区域趋势至关重要，因为法律规范、报销环境、生产能力和患者准入模式在不同地区差异显着。在美洲，成熟的监管管道、完善的商业性报销机制和集中的生产生态系统支持加速临床开发和商业化，但市场准入需要强有力的卫生经济学证据和支付方的积极参与。另一方面，欧洲、中东和非洲地区则呈现异质性。儘管欧盟内部存在协调一致的监管机制，但在报销时间表和卫生技术评估 (HTA) 的预期方面仍存在差异。此外，中东和非洲的一些市场为建立策略伙伴关係关係以扩大市场准入提供了机会，但同时也需要製定个人化的监管和分销策略。

整合平台差异化、生产规模和合作伙伴关係模式的企业策略，决定了哪些公司能够从临床潜力走向商业性成功。

一家癌症基因治疗公司的发展轨迹取决于三个相互依存的因素：其科学平台的深度、生产和规模化能力，以及其在伙伴关係和许可方面的策略方针。拥有专有载体工程和递送平台的公司可以获得差异化的临床优势，但要将这种优势转化为临床验证，需要透过稳健的临床前模型和优化的CMC（化学、生产和品管）流程来谨慎地降低风险。同时，透过自有投资或长期契约製造伙伴关係获得可靠生产能力的公司可以降低执行风险，并确保按计划完成III期临床试验和商业化。因此，製造地的规模和品管方面的专业知识往往是决定性的差异化因素。

生物製药产业领导者可采取切实可行的策略步骤，以降低技术风险、加强供应链，并与监管机构和支付者协调，从而加快产品上市速度。

产业领导企业应采取多管齐下的行动计划，同时应对技术风险、供应链脆弱性、监管复杂性以及与支付方的合作。首先，他们应优先考虑儘早选择载体和递送途径，并制定明确的决策标准来评估其可转化性、可生产性和免疫抗原性。这将减少下游流程中的失败，并使资金集中用于最可行的方案。其次，他们应投资于灵活的生产策略，包括与获得认证的契约製造伙伴关係、尽可能本地采购以及预留产能以降低关税和物流风险。这些措施将提高营运韧性，并增强快速扩大成功专案规模的能力。

采用透明且可重复的研究途径，结合对专家的初步访谈、对科学发现的二次整合以及定性检验，以支持可靠的结论。

本执行摘要的研究基础包括与主要相关人员的对话以及对二手资料的系统性整合，以得出平衡且可重复的结论。一手资料包括与临床研究人员、生产专家、监管顾问和商业领域领导者的结构化访谈和讨论，旨在了解实际限制、临床设计偏好和支付方的观点。这些讨论有助于解读载体类型、给药方法和临床策略之间的技术权衡，并有助于检验观察到的生产规模扩大和伙伴关係活动趋势。

整合临床、技术、监管和商业性因素，为不断发展的癌症基因治疗生态系统中的相关人员提供指导。

总而言之，癌症基因治疗正从以探索为主的领域转向以转化准确性、生产准备度和商业性远见为关键因素的综合领域。载体和递送方法的创新正在扩大治疗范围，而临床和监管方面的洞察则不断完善专案设计和患者选择。同时，供应链的考量和政策的变化正在影响营运决策，迫使企业将采购、生产和物流与策略发展计画相协调。因此，研发、生产、监管和商业团队之间的跨职能整合对于降低研发管线风险和加速病患获得治疗至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按载体类型分類的癌症基因治疗市场

  • 非病毒载体
    • 脂质奈米颗粒
    • 物理方法
    • 聚合物奈米粒子
  • 病毒载体
    • 腺结合病毒
    • 腺病毒
    • 慢病毒
    • 逆转录病毒

第九章 癌症基因治疗市场（依治疗方法划分）

  • Ex Vivo
  • In vivo

第十章 癌症基因治疗市场：依适应症划分

  • 血癌
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
  • 固体癌
    • 乳癌
    • 结肠癌
    • 肺癌
    • 摄护腺癌

第十一章 癌症基因治疗市场：依阶段划分

  • 临床试验
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 商业的
  • 临床前

第十二章 癌症基因治疗市场：依最终用户划分

  • 医院和诊所
  • 肿瘤中心
  • 研究机构

第十三章 癌症基因治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 癌症基因治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 癌症基因治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国癌症基因治疗市场

第十七章：中国癌症基因治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • Autolus Therapeutics plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • CARsgen Therapeutics Holdings Limited
  • Cellectis SA
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics, Inc.
  • Iovance Biotherapeutics, Inc.
  • Janssen Biotech, Inc.
  • Kite Pharma, Inc.
  • Novartis AG
  • Precigen, Inc.
  • Sarepta Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-B1685377A6FA

The Cancer Gene Therapy Market was valued at USD 3.30 billion in 2025 and is projected to grow to USD 3.97 billion in 2026, with a CAGR of 19.96%, reaching USD 11.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.30 billion
Estimated Year [2026] USD 3.97 billion
Forecast Year [2032] USD 11.81 billion
CAGR (%) 19.96%

Catalyzing the emergence of clinically viable cancer gene therapies through integrated scientific advances, delivery innovations, and pragmatic translational strategies

Cancer gene therapy sits at an inflection point where decades of foundational science are converging with pragmatic clinical execution and industrial-scale manufacturing. Over recent years, advances in vector engineering, delivery modalities, and molecular targeting have transitioned many concepts from laboratory proof-of-principle to human testing, and in selected cases to clinical adoption. Simultaneously, improvements in genomic profiling, patient stratification, and companion diagnostics are enabling more precise matching of therapeutic constructs to biologically defined populations, thereby improving the probability of clinical benefit and informing development prioritization.

Consequently, stakeholders across research, development, manufacturing, and commercialization must approach gene therapy with a dual lens: one that appreciates the unique scientific demands of nucleic acid delivery and one that anticipates regulatory, reimbursement, and operational realities. As a result, strategic planning today requires integrated thinking about vector selection, manufacturing capacity, clinical trial design, and payer engagement. By aligning translational science with practical implementation pathways, organizations can shorten the path from target validation to patient access while managing technical risk and capital deployment.

Emerging technological breakthroughs, regulatory recalibrations, and evolving commercial models are reshaping therapeutic design, manufacturing, and patient access pathways

Recent transformative shifts in the cancer gene therapy landscape are driven by intersecting technological, regulatory, and commercial dynamics that materially alter program risk profiles and go-to-market calculus. On the technology front, improvements in vector design, including optimized tropism and reduced immunogenicity, as well as innovations in nonviral delivery platforms such as lipid nanoparticles, have expanded the range of feasible indications and patient populations. At the same time, manufacturing technologies are scaling more reliably, enabling higher-quality vectors at improved yields and with more consistent analytical control, which reduces batch variability and supports multi-site clinical development.

From a regulatory and policy perspective, agencies are refining guidance to better address the unique safety and quality considerations of gene therapies, while payers and health technology assessment bodies are experimenting with value-based contracting and outcomes-linked reimbursement. Collectively, these shifts are lowering certain barriers to entry and increasing the strategic value of partnerships between small innovators and established manufacturers. Consequently, organizations that can combine deep translational expertise with robust manufacturing partnerships and proactive payer engagement will be best positioned to convert scientific promise into sustainable clinical impact.

Assessing the operational and strategic implications of United States tariff policy changes on raw material sourcing, supply chain resilience, and cross-border clinical operations

Policy interventions affecting cross-border trade, including tariff revisions and related customs measures, have begun to influence procurement, sourcing, and supply chain architecture for biologics and advanced therapy materials. Changes in tariff structures can increase the cost of imported raw materials such as specialty lipids, plasmid DNA production reagents, viral vector inputs, and single-use manufacturing components. These incremental input costs translate into higher operational budgets for both early-stage developers and contract manufacturing organizations, which in turn may affect decisions about supplier consolidation, near-sourcing, or vertical integration.

Moreover, tariffs exert secondary effects on logistics and inventory strategies. To mitigate exposure to unpredictable policy shifts, companies are increasingly evaluating dual-sourcing strategies, regionalized inventories, and investments in local manufacturing capability. Consequently, clinical programs with geographically distributed trial sites must balance the desire for global patient enrollment against the complexity and cost of cross-border product shipments and import/export compliance. Over time, these structural responses can reshape partnership models and influence where organizations choose to site critical manufacturing and fill-finish operations, thereby altering the economics and speed of clinical and commercial deployment.

Disaggregated clinical and commercial segmentation reveals how vector choice, therapeutic modality, indication complexity, development stage, and end users shape strategic priorities

A nuanced segmentation framework clarifies where clinical promise intersects with commercial practicality across vector modalities, therapeutic approaches, indications, development stages, and end users. When analyzed by vector type, distinctions between nonviral and viral vectors shape R&D priorities: nonviral vectors encompass lipid nanoparticles, physical methods, and polymeric nanoparticles, offering advantages in manufacturing scalability and reduced long-term immunogenicity concerns, while viral vectors include adeno-associated, adenoviral, lentiviral, and retroviral platforms that provide durable transgene expression and cell-specific delivery advantages but demand specialized manufacturing and safety monitoring. Complementing this, therapy type differentiates ex vivo and in vivo approaches, with ex vivo modalities leveraging autologous or allogeneic cell manipulation workflows and in vivo strategies emphasizing direct systemic or localized delivery to tissues.

Indication segmentation further refines clinical strategy. Hematological cancers, including leukemia, lymphoma, and myeloma, have been fertile ground for adoptive cell therapies and targeted gene modifications because of accessible cell sources and well-characterized biomarkers, whereas solid tumors such as breast cancer, colorectal cancer, lung cancer, and prostate cancer present delivery barriers and immunosuppressive microenvironments that necessitate novel targeting and combination approaches. Stage segmentation is equally consequential: preclinical work informs vector selection and nonclinical safety profiling, clinical trials span Phase I, Phase II, and Phase III with escalating complexity in endpoint selection and operational scale, and commercial programs require robust quality systems and distribution networks. Finally, end users such as hospitals and clinics, specialized oncology centers, and research laboratories impose distinct demands on product presentation, cold chain logistics, training requirements, and reimbursement interactions. Taken together, these interlocking segmentation dimensions determine technology risk, capital intensity, partner selection, and commercialization pathways.

Regional competitive contours and patient access narratives across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated development and commercialization strategies

Regional dynamics matter because regulatory frameworks, reimbursement environments, manufacturing capacity, and patient access models differ substantially across geographies. In the Americas, mature regulatory pathways, established commercial reimbursement mechanisms, and concentrated manufacturing ecosystems support accelerated clinical development and commercialization, but market access requires robust health economic evidence and payer engagement. Conversely, Europe, Middle East & Africa exhibit heterogeneity: EU jurisdictions offer coordinated regulatory mechanisms yet diverge on reimbursement timelines and HTA expectations, while certain markets in the Middle East and Africa present opportunities for strategic partnerships to expand access but necessitate tailored regulatory and distribution strategies.

In the Asia-Pacific region, rapid investments in local manufacturing, rising clinical trial activity, and growing government support for biotechnology create fertile conditions for clinical translation and regional supply chains. However, differences in regulatory harmonization, patient population genetics, and healthcare infrastructure mean that go-to-market plans must be regionally adapted. Therefore, organizations should prioritize regulatory intelligence, localized clinical pathways, and supply chain resiliency when establishing presence across the Americas, Europe, Middle East & Africa, and Asia-Pacific to ensure that development timelines and commercial rollouts remain aligned with regional realities.

Company strategies that integrate platform differentiation, manufacturing scale, and collaborative partnership models determine who advances from clinical promise to commercial impact

Company-level trajectories in cancer gene therapy are driven by three interdependent factors: the depth of scientific platform, manufacturing and scale capabilities, and the strategic posture toward partnerships and licensing. Organizations with proprietary vector engineering or delivery platforms can capture differentiated clinical advantages, but translating those advantages into clinical proof requires careful de-risking through robust preclinical models and optimized CMC pathways. In parallel, companies that secure reliable manufacturing capacity-either through in-house investment or long-term contract manufacturing partnerships-reduce execution risk and maintain timelines for pivotal studies and commercial launches. Thus, manufacturing footprint and quality control expertise often become decisive differentiators.

Furthermore, firms adopting collaborative business models that combine early-stage innovation with established commercial or manufacturing partners tend to accelerate patient access while preserving upside through milestone and royalty structures. Strategic alliances that align clinical development plans, regulatory submission strategies, and market access evidence generation help firms navigate HTA negotiations and payer dialogues. Ultimately, the most successful companies will be those that integrate scientific differentiation with pragmatic manufacturing strategies and thoughtful commercial partnerships to move therapies from proof-of-concept to reliable patient delivery.

Actionable strategic measures for biopharma leaders to reduce technical risk, reinforce supply chains, and align regulatory and payer engagement for accelerated access

Industry leaders should adopt a multi-pronged action plan that addresses technical risk, supply chain fragility, regulatory complexity, and payer engagement concurrently. First, prioritize vector and delivery selection early with clear decision gates that weigh translatability, manufacturability, and immunogenicity; this reduces downstream attrition and focuses capital on the most viable constructs. Second, invest in flexible manufacturing strategies that include qualified contract manufacturing partnerships, near-sourcing where feasible, and contingency capacity to mitigate tariff and logistics risks. These moves improve operational resilience and accelerate the ability to scale successful programs.

Third, engage regulators and payers proactively to align on evidentiary needs, safety monitoring frameworks, and value demonstration pathways; early alignment reduces the risk of late-stage surprises and facilitates smoother reimbursement discussions. Fourth, design clinical programs that incorporate robust biomarker strategies and adaptive elements to enhance patient selection and endpoint sensitivity. Finally, pursue partnerships that augment internal capabilities-whether for manufacturing, regulatory expertise, or commercial infrastructure-so that scientific innovators can leverage complementary strengths and accelerate patient access. Taken together, these actions create a pragmatic roadmap for converting scientific innovation into durable clinical and commercial outcomes.

A transparent and reproducible research approach combining primary expert interviews, secondary scientific synthesis, and qualitative validation to support robust conclusions

The research underpinning this executive summary integrated primary stakeholder engagement with systematic secondary synthesis to ensure balanced, reproducible conclusions. Primary inputs included structured interviews and consultations with clinical investigators, manufacturing experts, regulatory advisors, and commercial leaders to capture real-world operational constraints, clinical design preferences, and payer perspectives. These discussions informed the interpretation of technical tradeoffs between vector types, delivery methods, and clinical strategies, and helped validate observed trends in manufacturing scale-up and partnership activity.

Secondary research involved a comprehensive review of peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures to map technological developments and regulatory evolution. Throughout the process, qualitative validation steps such as cross-checking assertions with multiple independent experts and reconciling divergent viewpoints were applied to reduce bias. Finally, findings were synthesized to highlight strategic implications rather than to produce proprietary market metrics, ensuring the analysis emphasizes actionable intelligence for decision-makers while remaining transparent about methodology and evidence sources.

Synthesis of clinical, technical, regulatory, and commercial considerations to guide stakeholders through the evolving gene therapy oncology ecosystem

In summary, cancer gene therapy is transitioning from a predominantly exploratory field to one in which translational fidelity, manufacturing readiness, and commercial foresight jointly determine success. Vector and delivery innovations broaden the therapeutic scope, while clinical and regulatory learnings refine program design and patient selection. Meanwhile, supply chain considerations and policy shifts influence operational choices, compelling organizations to align sourcing, manufacturing, and logistics with strategic development plans. As a result, cross-functional integration across R&D, manufacturing, regulatory, and commercial teams is essential to de-risk pipelines and accelerate patient access.

Looking ahead, the ecosystem will reward entities that combine rigorous translational science with disciplined program management and strategic partnerships. By focusing on modular manufacturing investments, proactive regulatory engagement, and evidence generation that resonates with payers, developers can improve the predictability of development pathways and enhance the likelihood of sustainable clinical impact. Ultimately, careful orchestration of technical, operational, and commercial activities will determine which therapies achieve broad patient adoption and which programs stall despite promising biology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Gene Therapy Market, by Vector Type

  • 8.1. Nonviral Vectors
    • 8.1.1. Lipid Nanoparticles
    • 8.1.2. Physical Methods
    • 8.1.3. Polymeric Nanoparticles
  • 8.2. Viral Vectors
    • 8.2.1. Adeno-Associated
    • 8.2.2. Adenoviral
    • 8.2.3. Lentiviral
    • 8.2.4. Retroviral

9. Cancer Gene Therapy Market, by Therapy Type

  • 9.1. Ex Vivo
  • 9.2. In Vivo

10. Cancer Gene Therapy Market, by Indication

  • 10.1. Hematological Cancers
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
    • 10.1.3. Myeloma
  • 10.2. Solid Tumors
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Prostate Cancer

11. Cancer Gene Therapy Market, by Stage

  • 11.1. Clinical Trials
    • 11.1.1. Phase I
    • 11.1.2. Phase II
    • 11.1.3. Phase III
  • 11.2. Commercial
  • 11.3. Preclinical

12. Cancer Gene Therapy Market, by End User

  • 12.1. Hospitals And Clinics
  • 12.2. Oncology Centers
  • 12.3. Research Laboratories

13. Cancer Gene Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Gene Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Gene Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cancer Gene Therapy Market

17. China Cancer Gene Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. Autolus Therapeutics plc
  • 18.7. Bayer AG
  • 18.8. BioMarin Pharmaceutical Inc.
  • 18.9. BioNTech SE
  • 18.10. bluebird bio, Inc.
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Candel Therapeutics, Inc.
  • 18.13. CARsgen Therapeutics Holdings Limited
  • 18.14. Cellectis S.A.
  • 18.15. CRISPR Therapeutics AG
  • 18.16. F. Hoffmann-La Roche Ltd
  • 18.17. Fate Therapeutics, Inc.
  • 18.18. Iovance Biotherapeutics, Inc.
  • 18.19. Janssen Biotech, Inc.
  • 18.20. Kite Pharma, Inc.
  • 18.21. Novartis AG
  • 18.22. Precigen, Inc.
  • 18.23. Sarepta Therapeutics, Inc.
  • 18.24. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)